hydroxychloroquine has been researched along with Abortion, Recurrent in 9 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This double-blind placebo-controlled study investigated the effect of hydroxychloroquine on pregnancy outcomes in people with unexplained recurrent pregnancy loss (URPL)." | 9.51 | The effect of hydroxychloroquine on pregnancy outcomes in patients with unexplained recurrent pregnancy loss: a placebo-controlled study "pilot study". ( Abiri, A; Dehpour, AR; Moini, A; Pirjani, R; Rabiei, M; Sepidarkish, M, 2022) |
| " Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties." | 9.05 | Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. ( Alavi, Z; de Moreuil, C; Pasquier, E, 2020) |
| "This double-blind placebo-controlled study investigated the effect of hydroxychloroquine on pregnancy outcomes in people with unexplained recurrent pregnancy loss (URPL)." | 5.51 | The effect of hydroxychloroquine on pregnancy outcomes in patients with unexplained recurrent pregnancy loss: a placebo-controlled study "pilot study". ( Abiri, A; Dehpour, AR; Moini, A; Pirjani, R; Rabiei, M; Sepidarkish, M, 2022) |
| " Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties." | 5.05 | Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. ( Alavi, Z; de Moreuil, C; Pasquier, E, 2020) |
| " Current treatment of patients with antiphospholipid syndrome (APS) during pregnancy with heparin and aspirin can act by preventing clot formation and improving live birth rates, but other obstetric morbidities remain high, especially in patients with a history of thrombotic events." | 4.90 | Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? ( de Jesús, GR; de Jesús, NR; Levy, RA; Rodrigues, G, 2014) |
| "Hydroxychloroquine (HCQ) is a molecule with extensive safety data during pregnancy." | 2.90 | Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study. ( Bohec, C; Bretelle, F; Chauleur, C; Cogulet, V; de Saint-Martin, L; Hannigsberg, J; Lejeune-Saada, V; Marhic, G; Merviel, P; Mottier, D; Pasquier, E; Plu-Bureau, G, 2019) |
| "Recurrent spontaneous abortion is one of the common complications in women of childbearing age during pregnancy." | 1.48 | [Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome]. ( Li, XY; Liu, XY; Zhao, JX, 2018) |
| "An autoimmune disease was present in seven (29%) cases." | 1.42 | Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study. ( Botta, A; Bucourt, M; Carbillon, L; Chollet-Martin, S; Chudzinski, A; Cornelis, F; Costedoat-Chalumeau, N; De Carolis, S; Emmanuelli, V; Fain, O; Hachulla, E; Masseau, A; Mekinian, A; Montestruc, F; Nicaise, P; Revaux, A; Subtil, D; Theulin, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Moini, A | 1 |
| Sepidarkish, M | 1 |
| Dehpour, AR | 1 |
| Rabiei, M | 1 |
| Abiri, A | 1 |
| Pirjani, R | 1 |
| de Moreuil, C | 1 |
| Alavi, Z | 1 |
| Pasquier, E | 2 |
| Yang, S | 1 |
| Ni, R | 1 |
| Lu, Y | 2 |
| Wang, S | 1 |
| Xie, F | 1 |
| Zhang, C | 1 |
| Lu, L | 1 |
| Dong, Y | 1 |
| Xia, Y | 1 |
| Wang, X | 1 |
| Kemp, M | 1 |
| Thomas, W | 1 |
| Li, XY | 1 |
| Zhao, JX | 1 |
| Liu, XY | 1 |
| de Saint-Martin, L | 1 |
| Marhic, G | 1 |
| Chauleur, C | 1 |
| Bohec, C | 1 |
| Bretelle, F | 1 |
| Lejeune-Saada, V | 1 |
| Hannigsberg, J | 1 |
| Plu-Bureau, G | 1 |
| Cogulet, V | 1 |
| Merviel, P | 1 |
| Mottier, D | 1 |
| de Jesús, GR | 1 |
| Rodrigues, G | 1 |
| de Jesús, NR | 1 |
| Levy, RA | 1 |
| Mekinian, A | 1 |
| Costedoat-Chalumeau, N | 1 |
| Masseau, A | 1 |
| Botta, A | 1 |
| Chudzinski, A | 1 |
| Theulin, A | 1 |
| Emmanuelli, V | 1 |
| Hachulla, E | 1 |
| De Carolis, S | 1 |
| Revaux, A | 1 |
| Nicaise, P | 1 |
| Cornelis, F | 1 |
| Subtil, D | 1 |
| Montestruc, F | 1 |
| Bucourt, M | 1 |
| Chollet-Martin, S | 1 |
| Carbillon, L | 1 |
| Fain, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Prévention Des Fausses Couches Spontanées Répétées Par Hydroxychloroquine. Essai thérapeutique Multicentrique, randomisé, en Double Insu, Contre Placebo[NCT03165136] | Phase 3 | 300 participants (Anticipated) | Interventional | 2017-12-04 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxychloroquine and Abortion, Recurrent
| Article | Year |
|---|---|
Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage.
Topics: Abortion, Habitual; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2020 |
Antiphospholipid syndrome in obstetrics.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; | 2018 |
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Growth Retarda | 2014 |
3 trials available for hydroxychloroquine and Abortion, Recurrent
| Article | Year |
|---|---|
The effect of hydroxychloroquine on pregnancy outcomes in patients with unexplained recurrent pregnancy loss: a placebo-controlled study "pilot study".
Topics: Abortion, Habitual; Double-Blind Method; Female; Humans; Hydroxychloroquine; Infant; Pregnancy; Preg | 2022 |
A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIv
Topics: Abortion, Habitual; COVID-19; Female; Fetus; Humans; Hydroxychloroquine; Immunosuppressive Agents; M | 2020 |
Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study.
Topics: Abortion, Habitual; Administration, Oral; Double-Blind Method; Female; France; Gestational Age; Huma | 2019 |
3 other studies available for hydroxychloroquine and Abortion, Recurrent
| Article | Year |
|---|---|
Effect of hydroxychloroquine on antiphospholipid antibodies-inhibited endometrial angiogenesis.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Endothelial Cells; Fema | 2022 |
[Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome].
Topics: Abortion, Habitual; Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2018 |
Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study.
Topics: Abortion, Habitual; Adult; Aspirin; Autoantibodies; Autoimmune Diseases; Cell Movement; Chorionic Vi | 2015 |